COVID-19
Human anti-SARS-CoV-2 antibodies
Neurimmune is identifying human antibodies for the treatment of Covid-19 patients by applying its RTMTM platform. Neurimmune’s scientists discover human antibodies against SARS-CoV-2 from immune cells of patients who recovered from Covid-19.
High-throughput immunoglobulin sequence analysis and robotic characterization of antibodies is being applied to identify highly potent, neutralizing human antibodies against different target structures of SARS-CoV-2 for therapeutic applications.
Progressive Multifocal Leukoencephalopathy (PML)
Human anti-JC polyomavirus VP1-specific antibodies
Neurimmune successfully identified using its RTMTM technology platform JC polyomavirus (JCPyV)-specific human monoclonal antibodies from patients who recovered from PML–immune reconstitution inflammatory syndrome (IRIS).
A high-throughput immunoglobulin sequence analysis led to the generation of highly potent human antibodies with exquisite specificity for JCPyV, neutralizing activity, recognition of all tested JCPyV PML variants and ultra-high affinity. These antibodies are promising drug candidates for the development of a treatment of PML.
